

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Venetoclax with low dose cytarabine for untreated
acute myeloid leukaemia when intensive chemotherapy is
unsuitable**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

N/A – no potential equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No potential equality issues were raised in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The committee highlighted that venetoclax could provide an effective treatment option for older people who have not benefitted from other recent advances in treatment, and that anyone who can't easily travel to a major hospital may particularly benefit from being able to take venetoclax at home.
--

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

The committee considered these potential issues but noted that recommendations would apply to all patients, regardless of age or location. It concluded that no equality issues relevant to the recommendations had been identified.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, section 3.13.

Approved by Associate Director (name): Ross Dent

Date: 23/11/2021

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable